PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9847433-4 1998 IL-5 production by Dermatophagoides farinae -specific T-cell lines, eosinophil percentages, and eosinophil cationic protein (ECP) in induced sputum and airway responsiveness to allergen and histamine were evaluated before and after treatment. Histamine 190-199 interleukin 5 Homo sapiens 0-4 9569243-0 1998 Histamine affects interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the airways and blood. Histamine 0-9 interleukin 5 Homo sapiens 33-46 9569243-2 1998 This study describes the effects of histamine on anti-CD3-induced production of IL-4, IL-5, and IFN-gamma by T cell clones from subjects with allergic asthma and healthy subjects. Histamine 36-45 interleukin 5 Homo sapiens 86-90 7579337-7 1995 Preincubation of mast cells with SCF, IL-4, IL-5, or IL-6 for 24 hours during sensitization with IgE enhanced IgE/anti-IgE antibody-induced histamine release from mast cells, whereas IL-3 showed a negligible effect. Histamine 140-149 interleukin 5 Homo sapiens 44-48 9182905-2 1997 We examined the effect of histamine on the release of the Th2-associated cytokines IL-4 and IL-5 and the Th1-associated cytokine IFN-gamma by 30 CD4+ T cell clones from peripheral blood or bronchial biopsy of one atopic subject. Histamine 26-35 interleukin 5 Homo sapiens 92-96 9182905-6 1997 Histamine had a heterogeneous and insignificant effect on IL-5 production. Histamine 0-9 interleukin 5 Homo sapiens 58-62 7879707-0 1994 Histamine increases anti-CD3 induced IL-5 production of TH2-type T cells via histamine H2-receptors. Histamine 0-9 interleukin 5 Homo sapiens 37-41 7543541-2 1995 Preincubating basophil-containing mononuclear cells with 0.01 to 10 ng/ml IL-3 or IL-5 for 15 min at 37 degrees C caused a concentration-dependent enhancement of histamine release stimulated by 1.5 microM MBP. Histamine 162-171 interleukin 5 Homo sapiens 82-86 7543541-5 1995 A 10- to 15-min preincubation with IL-5 maximally increased the level of MBP-stimulated histamine release. Histamine 88-97 interleukin 5 Homo sapiens 35-39 7543541-6 1995 Preincubation of cells with 10 ng/ml IL-3 or IL-5 reduced the MBP concentrations required for histamine release by three- to fourfold and enhanced the rate of MBP-induced histamine release. Histamine 94-103 interleukin 5 Homo sapiens 45-49 7543541-6 1995 Preincubation of cells with 10 ng/ml IL-3 or IL-5 reduced the MBP concentrations required for histamine release by three- to fourfold and enhanced the rate of MBP-induced histamine release. Histamine 171-180 interleukin 5 Homo sapiens 45-49 7480030-1 1995 Histamine inhibits IL-4 secretion from T helper type 2 cells but enhances IL-5 secretion from the same cells. Histamine 0-9 interleukin 5 Homo sapiens 74-78 7879707-3 1994 We have investigated the effect of histamine on anti-CD3 induced IL-4 and IL-5 production by TH2 cells. Histamine 35-44 interleukin 5 Homo sapiens 74-78 7879707-4 1994 Histamine in concentrations between 10(-7) and 10(-5) mol/l concentration-dependently increased anti-CD3 induced IL-5 production up to 120%, whereas IL-4 production was not affected. Histamine 0-9 interleukin 5 Homo sapiens 113-117 7879707-5 1994 The activity of histamine in increasing IL-5 production was mimicked by the H2-receptor agonist dimaprit. Histamine 16-25 interleukin 5 Homo sapiens 40-44 7879707-6 1994 Histamine induced increase in IL-5 production was inhibited by histamine H2-receptor antagonists, but remained unaffected by H1- or H3-receptor antagonists. Histamine 0-9 interleukin 5 Homo sapiens 30-34 7879707-8 1994 These results indicate that the histamine-mediated increase in anti-CD3 induced IL-5 production is mediated via H2-receptors. Histamine 32-41 interleukin 5 Homo sapiens 80-84 7879707-9 1994 Consequently, histamine released from mast cells and basophils during the early-phase allergic reaction may act as an important stimulatory signal for the initiation of the allergic inflammatory late-phase reaction by increasing local IL-5 production of allergen triggered TH2 cells. Histamine 14-23 interleukin 5 Homo sapiens 235-239 7544549-4 1994 Preincubation of leukocytes with IL-3, GM-CSF, or IL-5 (0.02-2 ng/ml), but not with IL-8 and SCF, caused a dose-dependent enhancement of antigen-induced basophilic histamine release in all subjects tested. Histamine 164-173 interleukin 5 Homo sapiens 50-54 8007458-5 1993 IL-3, GM-CSF, IL-5 and IGF-I enhanced basophil histamine release. Histamine 47-56 interleukin 5 Homo sapiens 14-18 7522070-4 1994 Further, SCF potentiated histamine release whatever the level of immunological control whereas potentiation by IL-5 primarily occurred when the amount of histamine release induced by the immunological control ranged between 5 and 10%. Histamine 154-163 interleukin 5 Homo sapiens 111-115 7522070-6 1994 Both SCF and, to a lesser extent, IL-5 potentiated anti-IgE-mediated histamine release regardless of passive sensitization of lung fragments. Histamine 69-78 interleukin 5 Homo sapiens 34-38 7522070-7 1994 Unlike what was observed with lung fragments, IL-3, GM-CSF and to a lesser extent IL-5, were potent enhancing agents of anti-IgE (1/2,000)-induced histamine release from leukocytes. Histamine 147-156 interleukin 5 Homo sapiens 82-86 8436904-7 1993 IgER-induced IL-4 synthesis and release by basophils cultured with IL-3 was rapid and complete after 6 h. In contrast to IL-3, other cytokines (IL-5, granulocyte/macrophage colony-stimulating factor, and nerve growth factor) that also prime basophils for enhanced histamine and leukotriene C4 release did not promote IgER-induced IL-4 synthesis. Histamine 264-273 interleukin 5 Homo sapiens 144-223 7684660-5 1993 IL-3, IL-5, IL-6, and GM-CSF enhanced significantly anti-IgE- and FMLP-induced histamine release. Histamine 79-88 interleukin 5 Homo sapiens 6-10 1389404-0 1992 In human nasal mucosa, interleukin-5 accumulates and degranulates eosinophils, as well as increases responsiveness to histamine. Histamine 118-127 interleukin 5 Homo sapiens 23-36 1380388-3 1992 administration of human recombinant interleukin-5 (rhIL-5; 100 or 300 ng) to isolated perfused lungs from guinea-pigs actively sensitized to ovalbumin induced an increased bronchoconstriction and release of thromboxane A2 (TXA2) and histamine into the lung effluent following the subsequent (10 min) intra-arterial injection of platelet-activating factor (PAF). Histamine 233-242 interleukin 5 Homo sapiens 36-49 7679699-8 1993 Other basophil primers for anti-IgE-dependent histamine release were IL-5, mast cell growth factor (c-kit ligand), and insulin-like growth factor II. Histamine 46-55 interleukin 5 Homo sapiens 69-73 1380308-2 1992 IL-3, GM-CSF, and IL-5 enhanced basophil histamine release and in-vitro survival, while G-CSF, M-CSF, and IL-4 had no enhancing activities at all. Histamine 41-50 interleukin 5 Homo sapiens 18-22 1701820-0 1990 Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. Histamine 23-32 interleukin 5 Homo sapiens 0-13 1706953-0 1991 Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Histamine 56-65 interleukin 5 Homo sapiens 0-13 1706953-4 1991 IL-5 stimulated a greater proportion of basophil-containing, histamine-positive, eosinophil-type colonies compared with GM-CSF, IL-3, or G-CSF. Histamine 61-70 interleukin 5 Homo sapiens 0-4 1706953-5 1991 IL-5 also stimulated dose-dependent increases in histamine content of alkaline-passaged, butyrate cotreated HL-60 cells. Histamine 49-58 interleukin 5 Homo sapiens 0-4 1706953-6 1991 The concentration of IL-5 required for half-maximal induction of HL-60 histamine content was similar within twofold to that needed for half-maximal stimulation of the multifactor dependent TF-1 erythroleukemic cell line. Histamine 71-80 interleukin 5 Homo sapiens 21-25 1701820-3 1990 However, at low concentrations (0.1-10 ng/ml), IL-5 rapidly primes basophils for enhanced histamine release and leukotriene C4 (LTC4) generation in response to all established basophil agonists. Histamine 90-99 interleukin 5 Homo sapiens 47-51 1700056-0 1990 Enhancement of human basophil histamine release by interleukin 5. Histamine 30-39 interleukin 5 Homo sapiens 51-64 1700056-3 1990 IL-5 enhanced basophil histamine release evoked by anti-IgE, formyl-methionyl-leucyl-phenylalanine, or ionophore A23187 at picomolar concentrations. Histamine 23-32 interleukin 5 Homo sapiens 0-4 12810348-4 2003 Histamine enhances the secretion of Th2 cytokines such as IL-4 (interleukin-4), IL-5, IL-10 and IL-13 and inhibits the production of Th1 cytokines IL-2 and IFNgamma (interferon-gamma) and monokine IL-12. Histamine 0-9 interleukin 5 Homo sapiens 80-84 1690180-6 1990 NGF synergistically enhanced IL-5 induced dose-dependent increases in histamine content and basophilic cell differentiation of myeloid leukemic HL-60 cells, but was only additive to similar effects of IL-3. Histamine 70-79 interleukin 5 Homo sapiens 29-33 12810348-7 2003 We have also demonstrated that the Jak-STAT (Janus kinase-signal transducers and activators of transcription) pathway is involved in histamine-mediated regulation of Th2 cytokines IL-5, IL-10, IL-13 and Th1 cytokine IFNgamma. Histamine 133-142 interleukin 5 Homo sapiens 180-184 17482857-11 2008 Histamine (10-100 microM) partially reversed IL-5-induced human eosinophil survival by enhancing apoptosis as assessed by measuring the relative DNA content of PI-stained cells. Histamine 0-9 interleukin 5 Homo sapiens 45-49 17482857-13 2008 Moreover, the reversal of IL-5-inhibited eosinophil apoptosis by histamine seemed not to utilize the conventional intracellular second-messenger pathways including cyclic AMP, protein kinase A or phospholipase C. Inhibition of caspase 6 and caspases 1, 10 or 12 reversed the effects of histamine but also inhibited apoptosis in general. Histamine 65-74 interleukin 5 Homo sapiens 26-30 17482857-0 2008 Histamine reverses IL-5-afforded human eosinophil survival by inducing apoptosis: pharmacological evidence for a novel mechanism of action of histamine. Histamine 0-9 interleukin 5 Homo sapiens 19-23 17482857-13 2008 Moreover, the reversal of IL-5-inhibited eosinophil apoptosis by histamine seemed not to utilize the conventional intracellular second-messenger pathways including cyclic AMP, protein kinase A or phospholipase C. Inhibition of caspase 6 and caspases 1, 10 or 12 reversed the effects of histamine but also inhibited apoptosis in general. Histamine 286-295 interleukin 5 Homo sapiens 26-30 17482857-0 2008 Histamine reverses IL-5-afforded human eosinophil survival by inducing apoptosis: pharmacological evidence for a novel mechanism of action of histamine. Histamine 142-151 interleukin 5 Homo sapiens 19-23 16449261-9 2006 Sputum IL-5 mRNA levels (but not the other cytokine mRNA levels) were also correlated with exhaled nitric oxide (eNO) and with bronchial hyperreactivity expressed as the histamine concentration resulting in a 20% decrease in forced expiratory volume in 1 second. Histamine 170-179 interleukin 5 Homo sapiens 7-11 11357887-6 2001 We then studied the effects of tyrphostin on histamine-mediated inhibition of IFNgamma production and histamine-mediated stimulation of IL-5 and IL-10 production. Histamine 102-111 interleukin 5 Homo sapiens 136-140 11357887-7 2001 Tyrphostin dose-dependently reversed the effects of histamine on IFNgamma, IL-5 and IL-10 production, as evident by ELISA. Histamine 52-61 interleukin 5 Homo sapiens 75-79 10848908-10 2000 This increase in the thapsigargin-induced histamine release correlated with the increase in serum IL-5 levels at 24 h after allergen challenge. Histamine 42-51 interleukin 5 Homo sapiens 98-102